marketcaparena

Cellectis S.A.

CLLS

About Cellectis

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

cellectis.com ↗

Employees
224
Business address
PARIS, LLE-DE-FRANCE
Fiscal year ends
December 31
Listed
Nasdaq · CLLS

Price

Share price

Daily closing price. The header shows the latest close, the market cap at that close and the change over the selected range. Hover or tap the chart to read any day.
$1.48
−$1.88 (−55.95%)past year
Market cap
$107M
At close
Sep 28, 2026

Share price vs index

Cellectis's share price and the index, each as its percentage change since the first day of the selected range. The shading shows the gap: green while Cellectis is ahead, orange while it is behind. The values at the end are each one's change over the range.

Revenue mix

Revenue by geography

FY24
Full year
Reported countries and regions in the chosen year or quarter. Known regions use standard geographic footprints. Hover shows the reported region total, never an allocation to individual countries. Ambiguous remainders are not mapped.

Geography growth

FY24
Year
Each country's or region's revenue in the chosen period against the same period a year earlier (YoY), so seasonal swings cancel out, or against the quarter before (QoQ). A year is always compared with the year before. Hover or tap a line to bring it forward.

Top geographies

FY24
Full year
Reported countries and regions in the chosen year or quarter, largest first, in the map's colours. The share of the disclosed geography shows only where the reported parts add up.

Income statement

Revenue, gross profit and net income

Q4 25
Full year
Quarter
Revenue, gross profit and net income on one scale, so their sizes can be compared period by period.

Income statement

FY25
Full year
How revenue becomes net income in the chosen year or quarter. Solid bars are totals; hatched bars are the costs taken off between them.
TotalAddedSubtracted

Operating leverage

FY25
Full year
Revenue growth against operating expense growth, each against the same quarter a year earlier. While revenue grows faster than opex, each extra dollar of sales keeps more profit.

Cash flow

Operating and free cash flow

FY25
Full year
Free cash flow is what is left of operating cash flow after capital expenditure. The gap between each pair of bars is that year's capex.

Cash flow statement

FY25
Full year
The reported movements behind the change in cash in the chosen year or quarter. Solid bars are totals; hatched bars are what was added or taken off between them.
TotalAddedSubtracted

Capital allocation

FY25
Full year
Operating cash flow above zero; what it was spent on below: capital expenditure, dividends and buybacks.

Stock-based compensation

FY25
Full year
Stock-based compensation reported in the cash flow statement each period. The line is that amount as a percentage of the same period's revenue.
Stock-based compensation% of revenue

Balance sheet

Assets, liabilities and equity

Q4 25
Full year
Quarter
The balance sheet at the end of the chosen year or quarter. What the company owns on the left, against what it owes and what belongs to shareholders on the right. Both columns add up to total assets.

War chest

Q4 25
Full year
Quarter
Cash and short-term investments held at each quarter end. The figure at the top of each column is the total.